I I think the the the last three would be comparable. Metformin I'm skeptical of. So RAPA, SGLT2, GLP1.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I I think the the the last three would be comparable. Metformin I'm skeptical of. So RAPA, SGLT2, GLP1.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
we could design an experiment where you had the placebo arm, the metformin arm, the rapamy arm, the SGLT2 inhibitor arm, and the GLP-1 agonist arm.
If we if we took a population of middle-aged healthy individuals Yeah. and we we could design an experiment where you had the placebo arm, the metformin arm, the rapamy arm, the SGLT2 inhibitor arm, and the GLP-1 agonist arm. What is your prediction in length of life or additional years of life given in that six arm study or whatever it is?